| License: Creative Commons Attribution Non-commercial 4.0 PDF - Published Version (588kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-524265
- DOI to cite this document:
- 10.5283/epub.52426
This publication is part of the DEAL contract with Wiley.
Abstract
The introduction of clinical antibodies against programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has revolutionized cancer treatment. Immune checkpoint blockade has enormous therapeutic potential and is widely prescribed for treating various cancers. However, immune-related adverse events in checkpoint blockade-treated patients are common and limit its clinical ...
Owner only: item control page
Download Statistics